Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection. - Mechanism of Action & Protocol.

September 26, 2023 - Lenvervimab (INN; development code GC1102) is a monoclonal antibody that is being investigated for hepatitis B.

In 1990, a murine mAb was used ... been tested in humans and led to a notable reduction of HBsAg levels.12 A recent paper using a human anti-HBs mAb (GC1102) showed significant reductions of HBsAg levels after administration, but rebounds were common.13 All these studies, however, ...

Lenvervimab (GC1102) is a IgG1-type recombinant human hepatitis B Immunoglobulin. Lenvervimab can be used for research of hepatitis B virus infection. Buy Anti-infection inhibitor Lenvervimab (GC1102) from AbMole BioScience.

GC1102 is a new recombinant hepatitis B immunoglobulin (HBIG) from Chinese Hamster Ovary (CHO) cells. It is a monoclonal antibody and has high affinity and avidity to hepatitis B surface antigen and several advantages compared to HBIG derived from blood plasma of human donors.

May 17, 2023 - Log in or create an account for full access to this data · Explore a selection of our essential drug information below, or:

This is a proof-of-concept study for GC1102 to demonstrate preventing the recurrence of hepatitis B virus (HBV) infection following liver transplantation and a dose-finding study to determine its optional dose.

January 18, 2018 - The clinical 2/3 trial is expected to take around 5 years to complete, with patient enrollment beginning in early 2018.

Chronic hepatitis B virus (HBV) infection remains a global health burden. Timely and effective antiviral therapy is beneficial for patients with HBV infection. With existing antiviral drugs, including nucleos(t)ide analogs and interferon-alfa, ...

The purpose of this study is to evaluate the efficacy and safety of GC1102 in combination of Nucleo(t)ide analogues (NAs) in patients with chronic hepatitis B

Hepatitis B Virus (HBV) is a hepadnavirus that is the principal pathogen underlying viral liver disease in human populations. In this study, we describe the isolation and characterization of a fully human monoclonal antibody for HBV. This HuMab was isolated by a combinatorial screen of the ...

This study is SAD(Single Ascending Dose)/MAD(Multiple Ascending Dose) study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of GC1102 (Recombinant Hepatitis B Human Immunoglobulin) in Chronic Hepatitis B Patients.

Download scientific diagram | Activity measurement of GC1102 by Abbott ARCHITECT AntiHBs against different dilution solutions for 10,000-, 20,000-, and 40,000-fold dilutions. Dilution solutions were 1% BSA in PBS (■), 5% BSA in PBS (•), 10% BSA in PBS (□), 20% BSA in PBS (♦), and dilution ...

This study is investigating GC1102 (Recombinant Hepatitis B Human Immunoglobulin) in Chronic Hepatitis B Patients. This study is composed with 2 Parts, Part A

Several methods for the quantification of human anti-HBs, an antibody to hepatitis B surface antigen (HBsAg), have been developed based on enzyme reaction, chemiluminescence, fluorescence, and radioactivity for application to human serum or plasma. ...

Abstract Over 250 million people are living with chronic infection caused by the hepatitis B virus (HBV). HBV has three surface proteins, namely small (SHBs), medium (MHBs) and large (LHBs), and th...

The virus neutralizing efficacy of HB-C7A, a human monoclonal antibody raised against the surface antigen of hepatitis B virus (HBsAg), was proved usi…

Chronic hepatitis B is a global public health problem, and coinfection with hepatitis delta virus (HDV) worsens disease outcome. Here, we describe a h…